Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans

NCT00122473 is registered in ClinicalTrials.gov with Dermatologic Cooperative Oncology Group as lead sponsor.

NCT NCT00122473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00122473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans
Lead sponsor
Dermatologic Cooperative Oncology Group
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2004
Completion date
January 31, 2007
Enrollment
30
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dermatofibrosarcoma